Thymidine Phosphorylase Inhibitor Drug Class List

Drugs in Drug Class: Thymidine Phosphorylase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taiho Oncology	LONSURF	tipiracil hydrochloride; trifluridine	TABLET;ORAL	207981-001	Sep 22, 2015	AB	RX	Yes	No
Taiho Oncology	LONSURF	tipiracil hydrochloride; trifluridine	TABLET;ORAL	207981-002	Sep 22, 2015	AB	RX	Yes	Yes
Taiho Oncology	LONSURF	tipiracil hydrochloride; trifluridine	TABLET;ORAL	207981-001	Sep 22, 2015	AB	RX	Yes	No

Market Dynamics and Patent Landscape for Thymidine Phosphorylase Inhibitor Drugs

Last updated: April 23, 2026

Thymidine phosphorylase inhibitors (TPIs) target the nucleotide salvage pathway, with clinical development anchored in oncology where thymidine phosphorylase (TYMP) is implicated in tumor biology and angiogenesis. Market dynamics for TPIs are shaped by (i) the dominance of combination regimens in oncology, (ii) the “line-of-therapy” economics driven by progression-free survival (PFS) and toxicity, and (iii) patent exclusivity concentrated among a small set of chemical matter and formulation/fixed-dose combinations.

What defines the thymidine phosphorylase inhibitor market?

Therapeutic focus

TPIs are primarily developed in cancer, most often as combination components. The market need is not monotherapy efficacy alone; it is value in combination through modulation of nucleotide metabolism and associated pharmacodynamics.

Economic drivers

Key economics in TPIs track the same levers seen across oncology combination products:

• Access and reimbursement determined by added benefit in clinically meaningful endpoints (PFS, overall survival, response rate) versus standard-of-care.
• Dosing complexity (fixed dosing versus separate administration) affects real-world adoption and margin.
• Toxicity profile impacts tolerability and dose continuity, which directly affects dose intensity and net clinical benefit.

Competitive setting

Competition typically comes from:

• Other agents in the same regimen lines (including thymidylate pathway targeting agents, antifolates, and broader anti-cancer combination standards).
• Different formulations or analogs that improve convenience or safety.
• Companies using TYMP biology data for next-generation TKIs or metabolic modulators, even when mechanistic labels vary.

Which thymidine phosphorylase inhibitors have the clearest commercial and patent footprints?

Pegylated/modified nucleoside metabolism inhibitors used in cancer combinations

The most established commercial anchor associated with thymidine phosphorylase inhibition is tipiracil in fixed-dose combination products. Tipiracil is widely used as part of trifluridine/tipiracil (TAS-102), a regimen commonly classified as a thymidine phosphorylase inhibitor in oncology pharmacology contexts.

• Drug: trifluridine/tipiracil (TAS-102)
• Role of tipiracil: thymidine phosphorylase inhibition to modulate trifluridine metabolism and exposure
• Market function: sustained use in gastrointestinal and other solid tumor settings, where combination regimen positioning drives volume.

Patent landscape takeaway: for TAS-102, the patent moat has historically centered on (i) composition-of-matter for specific active components and/or crystalline forms, (ii) combination and dose ratios, and (iii) formulation/process claims. Over time, secondary filings (polymorphs, improved manufacturing, and method-of-use claims) extend exclusivity.

Other TPIs and development pipelines

Beyond TAS-102-linked tipiracil, the broader TPI category is more fragmented. Some candidates exist through academic or early-stage development, but the commercial market is concentrated around products that achieved regulatory adoption with a stable combination backbone.

How do patent cliffs and exclusivity extensions affect market supply?

Exclusivity mechanics that matter for TPIs

TPIs are exposed to multi-layer exclusivity mechanics common to combination oncology products:

• Primary composition-of-matter patents for active ingredient(s)
• Formulation patents (solid-state forms, granulations, tablets/capsules, stability claims)
• Method-of-use patents tied to specific indications and lines of therapy
• Regulatory exclusivity (market authorization data protection and exclusivity regimes) where applicable

Secondary patent strategy pattern

The most common strategy in this class is to extend lifecycle through:

• Polymorph/crystal form filings
• Manufacturing process optimizations
• Fixed-dose ratio claims
• Dosing schedule and regimen-of-use claims that map to pivotal trials

Market consequences

• Before cliff: suppliers often compete on contract manufacturing capacity, patient support programs, and inclusion in hospital formularies.
• After cliff: generic entry accelerates price pressure, especially where patents are not strong against generic carve-outs or where combination product manufacturing is straightforward.

What does the IP landscape look like at a filing level?

A complete filing-level map requires country-by-country legal status and claim-level analysis, which depends on authoritative legal databases and document families. Without that legal dossier, the only reliable structural description is the typical TPI patent architecture for marketed products:

1) Composition-of-matter and salts

• Targets active molecule structures (tipiracil and any salts/derivatives)
• Includes crystalline or solid-state definitions where available

2) Combination composition

• Fixed-dose ratio patents for trifluridine/tipiracil
• Capsules/tablets composition claims for specific excipients and manufacturing attributes

3) Method-of-use

• Indication patents in oncology
• Regimen and line-of-therapy patents (e.g., after prior therapy)

4) Manufacturing and formulation

• Improved yields
• Stability and shelf-life improvements
• Particle size and dissolution-related process parameters

Which regulatory and market dynamics shift uptake in oncology combinations?

Line-of-therapy economics

In oncology, payer adoption is strongly tied to positioning:

• First-line and later-line access are treated differently in many markets.
• TPIs that add benefit after prior therapies can gain durable adoption if they show net PFS/OS advantage with manageable toxicity.

Geographic adoption

Adoption trends follow:

• Trial footprint and data maturity in key jurisdictions
• Formulary inclusion and negotiated pricing
• Availability of combination product manufacturing and distribution

Real-world constraints

• Dosing adherence and side-effect management drive observed effectiveness
• Drug-drug interactions and overlapping toxicities with standard oncology regimens affect continuity

Where are the biggest patent value pools likely located?

Given the class structure and the dominance of fixed-dose combination products, the likely high-value pools are:

• Combination dose ratio and formulation claims (hard to “design around” without re-formulation)
• Crystalline form and stability-linked patents (often create barriers to generic entry if protected)
• Specific regimen or method-of-use claims tied to labeled indications

Key competitor dynamics inside the TPI category

Generic entry risk

• Generic erosion tends to be strongest once core composition-of-matter and fixed-dose combination patents expire or are narrowed.
• If secondary patents remain strong, generic entry may be delayed or restricted to carve-outs.

Brand retention

• Brand competition persists when:
  • formulation differences improve tolerability
  • patient support reduces discontinuation
  • clinicians prefer established safety experience

What due diligence should an investor or R&D team prioritize in TPIs?

A defensible diligence checklist for this class focuses on:

• Family mapping of the marketed TPI combination (active ingredients, fixed-dose ratio, dosage form, and manufacturing)
• Legal status by country for each patent in the family
• Claim coverage: whether method-of-use claims survive and are enforceable
• Design-around pathways: alternative ratios, alternative formulations, and new polymorph strategies
• Regulatory data exclusivity overlap with patent term

Key Takeaways

• Thymidine phosphorylase inhibitor value in oncology is driven by combination regimens where metabolic modulation improves exposure and regimen efficacy.
• Market dynamics are governed by payer and clinician uptake based on PFS/OS and toxicity, plus operational factors like fixed dosing and manufacturability.
• Patent landscapes for TPIs (notably tipiracil-containing regimens) typically concentrate value in composition-of-matter, fixed-dose combination, formulation/crystal form, and method-of-use claims.
• Lifecycle extension is usually achieved through secondary filings tied to solid-state/formulation and regimen-of-use, which can delay or shape generic entry.

---

FAQs

1) Are thymidine phosphorylase inhibitors primarily used as monotherapy?

No. The commercial and clinical positioning is predominantly in oncology combination regimens where TYMP modulation supports partner drug exposure and outcomes.

2) What patent types most often protect thymidine phosphorylase inhibitor products?

Composition-of-matter for active components, fixed-dose combination composition, formulation/crystal form, and method-of-use claims tied to labeled indications.

3) What most affects generic competition in this drug class?

Patent claim strength around fixed-dose ratios and formulations, plus whether solid-state and manufacturing patents remain in force in key markets.

4) Which market factors determine payer adoption for TPIs?

Incremental benefit in clinically meaningful endpoints, tolerability and dose continuity, and practical regimen convenience (especially fixed-dose administration).

5) Where do lifecycle extension opportunities typically sit for TPIs?

Secondary filings on polymorphs/crystalline forms, improved manufacturing processes, stability-enhancing formulation changes, and regimen-specific method-of-use claims.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Drug labels for trifluridine/tipiracil (TAS-102). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. (n.d.). Tas-102 EPAR and assessment documents. https://www.ema.europa.eu/
[3] World Intellectual Property Organization. (n.d.). Patent search and classification guidance (IPC/CPC resources). https://www.wipo.int/
[4] USPTO. (n.d.). Patent publication and legal status resources. https://www.uspto.gov/
[5] European Patent Office. (n.d.). Espacenet patent search. https://worldwide.espacenet.com/